Abstract
Premenstrual dysphoric disorder (PMDD) causes severe mood symptoms in the days before a period, and it can be treated. Antidepressants called SSRIs are a main option, and reviews find no clear difference between taking them only in the second half of the cycle and taking them every day, though the trials had a moderate or high risk of bias and daily use may do better for physical symptoms. Some hormonal treatments, such as certain contraceptive pills and medicines that pause the cycle, also ease symptoms, and further options exist for hard-to-treat cases. Cognitive behavioural therapy has some supporting evidence, though much of it is weak. Many questions are still uncertain, including long-term safety and newer medicines that act on brain chemistry.
Keywords: premenstrual dysphoric disorder, antidepressants, hormonal treatment, cognitive behavioural therapy, premenstrual syndrome
Get Help Now
Anyone who is thinking about suicide or self-harm, or who feels unable to cope, should contact a crisis line straight away. People in immediate danger should call their local emergency number.
- United States: the 988 Suicide & Crisis Lifeline takes calls and texts at 988 (988lifeline.org). - United Kingdom: Samaritans can be called free on 116 123 (samaritans.org). - Canada: the Suicide Crisis Helpline takes calls and texts at 9-8-8 (988.ca). - Australia: Lifeline can be called on 13 11 14 (lifeline.org.au).
This guide describes what published clinical guidelines and research reviews say about treating premenstrual dysphoric disorder. It is not a substitute for advice from a doctor or other health professional who knows a person's situation.
How Treatment Is Chosen
Expert groups treat PMDD as one of several premenstrual disorders (Nevatte et al., 2013). In the United States, the American College of Obstetricians and Gynecologists (ACOG) has published a guideline on treating these disorders (Ireland & Truehart, 2023). It covers adults and teenagers of reproductive age (Ireland & Truehart, 2023). Based on data from adults and expert consensus, it applies its recommendations to teenagers too, with a few exceptions (Ireland & Truehart, 2023). ACOG notes that many patients may benefit from combining more than one kind of treatment (Ireland & Truehart, 2023). The guideline also says the evidence is too thin to support some recommendations (Ireland & Truehart, 2023).
The International Society for Premenstrual Disorders (ISPMD) has issued expert consensus guidance on managing these disorders (Nevatte et al., 2013). For a later ISPMD consensus, members of the original consensus group submitted 66 proposed standards and ranked them to produce a set that clinics can use to check the quality of their care (Ismaili et al., 2016). These standards include a symptom diary kept for 2 months (Ismaili et al., 2016).
In the United Kingdom, the National Health Service (NHS) page on PMS, which also covers PMDD, describes lifestyle changes as a first step, followed by treatments guided by a family doctor (GP) (National Health Service, 2024). Its list includes antidepressants, cognitive behavioural therapy, and hormone treatments such as the combined pill (National Health Service, 2024). The NHS says a person who still has symptoms after trying these treatments may be referred to a specialist (National Health Service, 2024). It also advises calling 999 when PMDD comes with suicidal feelings (National Health Service, 2024). General information on depression treatment is on a separate page.
SSRIs
SSRIs belong to a group of medicines called serotonergic antidepressants (Nevatte et al., 2013). The ISPMD guidance found that SSRIs worked better than several other antidepressants, which did no better than placebo (Nevatte et al., 2013). SSRIs helped mood symptoms more than physical ones (Nevatte et al., 2013). They also seem to start working sooner in PMDD than in major depression (Hantsoo & Epperson, 2015). SSRIs can be taken every day or only in the second half of the cycle, called the luteal phase (Reilly et al., 2023). A 2023 meta-analysis, a study that combines earlier trials, pooled 8 trials with 460 women who had PMDD or severe PMS (Reilly et al., 2023). It found no significant difference between the two approaches in response, dropout or symptom change (Reilly et al., 2023). This held for PMDD and severe PMS when each was looked at alone (Reilly et al., 2023). However, every study in it had a moderate or high risk of bias (Reilly et al., 2023). The authors suggested that second-half dosing could be considered more often (Reilly et al., 2023). The ISPMD guidance found the two approaches similar overall, though daily use did better for physical symptoms (Nevatte et al., 2013).
A 2026 review gathered 16 studies and pooled 5 of them in a network meta-analysis, a method that ranks several treatments at once (Berni et al., 2026). It found both SSRIs and combined contraceptive pills effective for PMDD (Berni et al., 2026). One SSRI taken continuously ranked best among the antidepressants (Berni et al., 2026). The authors called for more trials comparing SSRIs with contraceptive pills directly, and only five studies were pooled (Berni et al., 2026). ACOG's guideline includes treatment recommendations for premenstrual disorders (Ireland & Truehart, 2023).
Hormonal Treatments
Some combined contraceptive pills contain a hormone called drospirenone (Ma & Song, 2023). A Cochrane review of 5 trials with 858 women, most with PMDD, found these pills may ease symptoms more than placebo (Ma & Song, 2023). Women taking them also reported gains in productivity, social life and relationships (Ma & Song, 2023). The evidence was low quality, and the placebo pill also had a clear effect (Ma & Song, 2023). Side effects may have been more common, probably including breast pain, and more women may have stopped because of them (Ma & Song, 2023). It is unknown whether the benefit lasts beyond three cycles or applies to less severe symptoms (Ma & Song, 2023).
GnRH agonists are medicines that pause the menstrual cycle (Naheed et al., 2025). A 2025 Cochrane review included 11 trials with 275 women; pooling 9 of them, it found with high certainty that GnRH agonists without add-back eased overall symptoms more than placebo (Naheed et al., 2025). More women stopped taking them because of side effects (Naheed et al., 2025). The review saw them as short-term relief only, because long-term safety is not confirmed (Naheed et al., 2025). The trials did not report long-term effects on bone, although the review notes that longer-term GnRH therapy carries a risk of osteoporosis (Naheed et al., 2025). Hormones given alongside them, called add-back therapy, were also studied, but that evidence was of low or very low certainty and did not show that add-back reduces side effects without lowering benefit (Naheed et al., 2025).
The ISPMD group found a large body of evidence for SSRIs, and found that stopping ovulation has been successful for managing symptoms (Nevatte et al., 2013). A 2022 scoping review found that SSRIs and contraceptive pills had the best evidence (Carlini et al., 2022). It described GnRH medicines and surgery as options for cases that do not respond to other treatment (Carlini et al., 2022).
Talking Therapy
Cognitive behavioural therapy (CBT), a form of talking therapy, appears on the NHS treatment list (National Health Service, 2024). A 2012 meta-analysis of 22 studies found that CBT and serotonergic antidepressants both gave small to medium gains over control groups (Kleinstäuber et al., 2012). For CBT, the effect sizes ranged from 0.24 to 0.70 (Kleinstäuber et al., 2012). Gains from CBT also showed at follow-up, though only the CBT studies had follow-ups (Kleinstäuber et al., 2012). The authors judged the results for both treatments unsatisfactory and suggested testing them together (Kleinstäuber et al., 2012).
A 2009 review of 9 trials in women with PMS included 5 trials of CBT (Busse et al., 2009). CBT lowered anxiety and depression, and may have reduced interference with daily life (Busse et al., 2009). The evidence was low quality, with design weaknesses and possible reporting bias (Busse et al., 2009). The results suggested that education did not help (Busse et al., 2009). Another 2009 review of 7 reports, 3 of them randomised trials, found little significant evidence for CBT in PMS or PMDD (Lustyk et al., 2009). It discussed the time CBT takes and how long its effects take to appear (Lustyk et al., 2009). The authors called for more rigorous trials (Lustyk et al., 2009).
Self-Help and Other Approaches
The NHS page on PMS lists lifestyle changes such as exercise, better sleep, diet, yoga and meditation (National Health Service, 2024). It also mentions painkillers such as ibuprofen or paracetamol, and not smoking or drinking too much alcohol (National Health Service, 2024). The NHS describes a symptom diary kept over at least 2 menstrual cycles (National Health Service, 2024). For supplements such as vitamin B6, calcium, vitamin D and magnesium, it says there is not much evidence they work (National Health Service, 2024). It advises people who take medicines to check with a GP or pharmacist before starting regular supplements (National Health Service, 2024). The NHS also says there is not much evidence that complementary therapies such as acupuncture and reflexology work (National Health Service, 2024).
Vitex agnus castus, also called chasteberry, is a plant remedy studied for PMS (Verkaik et al., 2017). A 2017 review found 17 trials, pooled 14, and found a large effect on PMS symptoms compared with placebo (Verkaik et al., 2017). Most trials had a high risk of bias, the size of the effect varied greatly between trials, and publication bias was suggested (Verkaik et al., 2017). The authors saw the result as exploratory, not conclusive (Verkaik et al., 2017).
Bright light therapy was reviewed in 2005 across 4 small trials with 55 people (Krasnik et al., 2005). In the three higher-quality trials, any effect on premenstrual depressive symptoms was small, and the true effect could have been zero (Krasnik et al., 2005). The authors said the evidence neither supports nor rules out its use (Krasnik et al., 2005).
What Is Still Uncertain
Reviews name several gaps. Studies of complementary treatments vary widely in quality and methods, and placebo responses in PMS studies have reached 50% in some (Carlini et al., 2022). Evidence for complementary treatments is modest (Carlini et al., 2022). Some studies mixed women with PMDD and women with severe PMS (Hantsoo & Epperson, 2015). Genetic studies have used small samples (Hantsoo & Epperson, 2015). PMDD appears to involve altered sensitivity to normal hormone changes rather than unusual hormone levels (Hantsoo & Epperson, 2015). Its causes look complex, and research on a possible role for inflammation in the brain has so far come mostly from animal studies, so more research is called for (Tiranini & Nappi, 2022).
Researchers are studying allopregnanolone, a neurosteroid (a steroid that acts on the brain), and its effect on the brain's GABA system (Tiranini & Nappi, 2022). A 2023 review judged this link a plausible source of PMDD symptoms (Sikes-Keilp & Rubinow, 2023). Hantsoo and Epperson suggested neurosteroids could be a target for new medicines (Hantsoo & Epperson, 2015). A medicine called sepranolone eased mood symptoms more than placebo, but not physical symptoms (Tiranini & Nappi, 2022). An extension study did not show that sepranolone worked better than placebo on its main outcome (Carlini et al., 2022). Other compounds in this area, such as dutasteride and ulipristal acetate, have shown promising findings in early clinical trials (Sikes-Keilp & Rubinow, 2023). The same review described the treatments already approved as less than ideal (Sikes-Keilp & Rubinow, 2023).
Learn More
More detail is in the full article on premenstrual dysphoric disorder and the guide to depression treatment. There is also a guide to PMDD symptoms.
Frequently Asked Questions
Can PMDD be treated?
Guidelines and reviews describe several treatment options. A 2022 review found that SSRIs and combined contraceptive pills had the best evidence (Carlini et al., 2022).
Is daily use the only way to take SSRIs for PMDD?
No. A 2023 meta-analysis found no significant difference between daily use and use only in the second half of the cycle, though its studies had a moderate or high risk of bias (Reilly et al., 2023).
Do contraceptive pills help with PMDD?
A Cochrane review found that pills containing drospirenone may ease symptoms (Ma & Song, 2023). The evidence ranged from very low to moderate quality, and the pills may lead to more side effects than placebo (Ma & Song, 2023).
Does talking therapy help with PMDD?
A 2012 meta-analysis found small to medium gains from cognitive behavioural therapy (Kleinstäuber et al., 2012). The authors still judged the results unsatisfactory (Kleinstäuber et al., 2012).
Do supplements or herbal remedies work for PMDD?
The NHS says there is not much evidence that supplements work (National Health Service, 2024). It advises people who take medicines to check with a GP or pharmacist before starting regular supplements (National Health Service, 2024).
When might a person with PMDD see a specialist or get urgent help?
The NHS says that someone who still has symptoms after trying the treatments a GP recommends may be referred to a specialist (National Health Service, 2024). It advises calling 999 when PMDD comes with suicidal feelings (National Health Service, 2024).
How This Article Was Prepared
This is a plain-language patient guide, not a systematic review. Following medical sourcing guidance, it rests on secondary sources rather than single studies: three clinical guidelines, 13 reviews of the research and one page from public health agencies.
- Included: 17 sources, each confirmed against the publisher's or indexer's own record. Seven read in full text and 10 from their abstracts. Agency and guideline pages were read on the publisher's own site. Abstracts came from PubMed and Crossref. - Identifiers: 16 references carry a PubMed ID and seven a PubMed Central ID, each confirmed by the National Library of Medicine against the cited DOI. - Retractions: 16 sources were checked for retractions and editorial notices; none was retracted. - Publication dates: three from the 2000s, five from the 2010s and nine from 2020 or later. - Checked against sources: each of the 92 cited sentences was matched to a passage in its source, and an independent reviewer checked the article against those sources over three passes before publication. - Limits: a short guide summarises selected sources and cannot cover every symptom or situation; it is not a diagnosis or a substitute for seeing a health professional. Each sentence was accepted only after its cited source had been searched for contrary evidence.
See our Editorial Policy for the full method.
References
ACOG Committee on Clinical Practice Guidelines-Gynecology (Yonkers, K. A., Ireland, L. D., & Truehart, A. I., listed contributors). (2023). Management of premenstrual disorders: ACOG Clinical Practice Guideline No. 7. Obstetrics & Gynecology, 142(6), 1516-1533. https://doi.org/10.1097/AOG.0000000000005426 PMID: 37973069
Berni, L. C., Nunes, L. R., & de Oliveira, R. C. S. (2026). Comparison of premenstrual dysphoric disorder treatment with antidepressants and combined oral contraceptives: a systematic review with network meta-analysis. Journal of Psychiatric Research, 194, 99-115. https://doi.org/10.1016/j.jpsychires.2025.12.046 PMID: 41468627
Busse, J. W., Montori, V. M., Krasnik, C., Patelis-Siotis, I., & Guyatt, G. H. (2009). Psychological intervention for premenstrual syndrome: A meta-analysis of randomized controlled trials. Psychotherapy and Psychosomatics, 78(1), 6-15. https://doi.org/10.1159/000162296 PMID: 18852497
Carlini, S. V., Lanza di Scalea, T., McNally, S. T., Lester, J., & Deligiannidis, K. M. (2022). Management of premenstrual dysphoric disorder: A scoping review. International Journal of Women's Health, 14, 1783-1801. https://doi.org/10.2147/IJWH.S297062 PMID: 36575726 · PMCID: PMC9790166
Hantsoo, L., & Epperson, C. N. (2015). Premenstrual dysphoric disorder: Epidemiology and treatment. Current Psychiatry Reports, 17(11), 87. https://doi.org/10.1007/s11920-015-0628-3 PMID: 26377947 · PMCID: PMC4890701
Ismaili, E., Walsh, S., O'Brien, P. M. S., Bäckström, T., Brown, C., Dennerstein, L., ... Yonkers, K. (2016). Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): Auditable standards for diagnosis and management of premenstrual disorder. Archives of Women's Mental Health, 19(6), 953-958. https://doi.org/10.1007/s00737-016-0631-7 PMID: 27378473
Kleinstäuber, M., Witthöft, M., & Hiller, W. (2012). Cognitive-behavioral and pharmacological interventions for premenstrual syndrome or premenstrual dysphoric disorder: A meta-analysis. Journal of Clinical Psychology in Medical Settings, 19(3), 308-319. https://doi.org/10.1007/s10880-012-9299-y PMID: 22426857
Krasnik, C., Montori, V. M., Guyatt, G. H., Heels-Ansdell, D., & Busse, J. W. (2005). The effect of bright light therapy on depression associated with premenstrual dysphoric disorder. American Journal of Obstetrics and Gynecology, 193(3), 658-661. https://doi.org/10.1016/j.ajog.2005.01.055 PMID: 16150256
Lustyk, M. K. B., Gerrish, W. G., Shaver, S., & Keys, S. L. (2009). Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: A systematic review. Archives of Women's Mental Health, 12(2), 85-96. https://doi.org/10.1007/s00737-009-0052-y PMID: 19247573
Ma, S., & Song, S. J. (2023). Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews, 2023(6), CD006586. https://doi.org/10.1002/14651858.CD006586.pub5 PMID: 37365881 · PMCID: PMC10289136
Naheed, B., Kuiper, J. H., O'Mahony, F., & O'Brien, P. M. (2025). Gonadotropin-releasing hormone (GnRH) analogues for premenstrual syndrome (PMS). Cochrane Database of Systematic Reviews, 2025(6), CD011330. https://doi.org/10.1002/14651858.CD011330.pub2 PMID: 40492482 · PMCID: PMC12150362
National Health Service. (2024, June 18). PMS (premenstrual syndrome). NHS. https://www.nhs.uk/conditions/pre-menstrual-syndrome/
Nevatte, T., O'Brien, P. M. S., Bäckström, T., Brown, C., Dennerstein, L., Endicott, J., Epperson, C. N., Eriksson, E., Freeman, E. W., Halbreich, U., Ismail, K., Panay, N., Pearlstein, T., Rapkin, A., Reid, R., Rubinow, D., Schmidt, P., Steiner, M., Studd, J., Sundström-Poromaa, I., & Yonkers, K. (2013). ISPMD consensus on the management of premenstrual disorders. Archives of Women's Mental Health, 16(4), 279-291. https://doi.org/10.1007/s00737-013-0346-y PMID: 23624686 · PMCID: PMC3955202
Reilly, T. J., Wallman, P., Clark, I., Knox, C. L., Craig, M. C., & Taylor, D. (2023). Intermittent selective serotonin reuptake inhibitors for premenstrual syndromes: A systematic review and meta-analysis of randomised trials. Journal of Psychopharmacology, 37(3), 261-267. https://doi.org/10.1177/02698811221099645 PMID: 35686687 · PMCID: PMC10074750
Sikes-Keilp, C., & Rubinow, D. R. (2023). GABA-ergic modulators: New therapeutic approaches to premenstrual dysphoric disorder. CNS Drugs, 37(8), 679-693. https://doi.org/10.1007/s40263-023-01030-7 PMID: 37542704
Tiranini, L., & Nappi, R. E. (2022). Recent advances in understanding/management of premenstrual dysphoric disorder/premenstrual syndrome. Faculty Reviews, 11, 11. https://doi.org/10.12703/r/11-11 PMID: 35574174 · PMCID: PMC9066446
Verkaik, S., Kamperman, A. M., van Westrhenen, R., & Schulte, P. F. J. (2017). The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis. American Journal of Obstetrics and Gynecology, 217(2), 150-166. https://doi.org/10.1016/j.ajog.2017.02.028 PMID: 28237870